Peer Review History

Original SubmissionDecember 13, 2023
Decision Letter - Sascha Köpke, Editor

PONE-D-23-41253Cognitive stimulation in activities of daily living for individuals with mild-to-moderate dementia (CS-ADL): study protocol for a randomised controlled trial.PLOS ONE

Dear Dr. Ryan,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. One reviewer recommends to apply the MRC framework for the development and evaluation of complex interventions and I would encourage the authors to adhere to this recommendation. It will definitely improve the protocol and should be helpful to successfully conduct the trial.

Please submit your revised manuscript by May 20 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Sascha Köpke

Academic Editor

PLOS ONE

Journal requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. We note that you have indicated that there are restrictions to data sharing for this study. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. 

Before we proceed with your manuscript, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see

https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Partly

Reviewer #2: Partly

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The paper is well written. I have only a few concerns.

1. Why a medium effect size (d=0.5) is chosen, please explain the rationale behind it.

2. Two primary outcome is chosen BADL and IADL. This will require multiple testing adjustment s otherwise type-1 error will be inflated. This is not addressed.

3. How the missing data will be handled?

4. The power analysis is based on two-sample t-tests, but the Statistical analysis section talks about regression-based model. They are not exactly the same, model for power analysis and primary analysis model should be as close possible as otherwise power analysis will be not be that meaningful.

Reviewer #2: Thank you very much for the invitation to review the manuscript by Brady and Ryan.

I read the study protocol with interest. The topic is certainly of interest and deserves closer attention.

This is clearly a complex intervention and therefore I wonder why the authors do not take the UK MRC framework for the development and evaluation of complex interventions into account. They do not report a programme theory or a logic model, do not consider a process evaluation and an economic evaluation. I wonder whether it is still timely to disregard the MRC framework, which has undoubtedly proven as golden standard.

Beyond this major comment, I have some minor comments, which might improve the manuscript.

The hypotheses passage is unnessessary and reads like a textbook information.

The sample size is rather low and I wonder whether the estimated effact size could be translated to a minimum clinical important difference. Apparently, a drop out rate has not been taken into account.

The authors do not completely adhere to the reporting statement. It remains unclear who will be in charge of the implementation of the allocation sequence and how this will be done.

Where will the intervention take place? Please add information.

Do the authors plan to implement a control mechanism whether blinding was successful?

A figure displaying the participant timelime is missing.

It remains unclear why an audit is not planned. Please comment on this. An audit would guarantee the quality of study procedures and data.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Reviewer Comments

Author responses

1. Why a medium effect size (d=0.5) is chosen, please explain the rationale behind it.

As specified in the ‘trial design’ subheading of the ‘Materials and Methods’ heading, while ideally a large effect size (d=0.2) is preferable, this would equate to a sample size of 199. It will be expected there will be challenges in the recruitment of 199 participants for the scale and timeframe of this study (approx. 1 year), and due to the challenges noted in recruiting this population in the literature (Langbaum et al., 2023). Therefore, for pragmatic reasons, recruitment will aim for the sample size of 34 (d=0.5).

2. Two primary outcome is chosen BADL and IADL. This will require multiple testing adjustment s otherwise type-1 error will be inflated. This is not addressed.

Thank you for your comment, this is an error on my part. I have adjusted the primary outcome to be ADL performance as opposed to both BADL and IADL, as multiple testing adjustment is not planned.

3. How the missing data will be handled?

It is possible that some data will be missing. To avoid this, attempts to follow-up with all participants will be made. However, if missing data remain, intention-to-treat analysis will be used to account for this.

4. The power analysis is based on two-sample t-tests, but the Statistical analysis section talks about regression-based model. They are not exactly the same, model for power analysis and primary analysis model should be as close possible as otherwise power analysis will be not be that meaningful.

Thank you for this advice, appropriate revisions have been made in text. Types of tests used in analysis will be chosen following completion of the dataset to assess whether the data is parametric or non-parametric.

This is clearly a complex intervention and therefore I wonder why the authors do not take the UK MRC framework for the development and evaluation of complex interventions into account. They do not report a programme theory or a logic model, do not consider a process evaluation and an economic evaluation. I wonder whether it is still timely to disregard the MRC framework, which has undoubtedly proven as golden standard.

Discussion of the MRC framework has been applied to the development of CS-ADL. A process evaluation and an economic evaluation are outside the scope of this study and will be focused on in future research.

The hypotheses passage is unnessessary and reads like a textbook information.

Thank you for your recommendation, this section has been removed from the manuscript.

The sample size is rather low and I wonder whether the estimated effact size could be translated to a minimum clinical important difference. Apparently, a drop out rate has not been taken into account.

Thank you for this suggestion. In line with this suggestion, it has been included in text that the minimum clinically important difference will be calculated based on the medium effect size, by dividing the difference in scores from baseline to posttreatment by the standard deviation of baseline scores (Franceschini et al. 2023).

In relation to the consideration of a drop-out rate, the following has been inserted in text: While this study is of a short duration, it is anticipated that there will be a minimum 10% attrition rate. This figure stems from Ritchie, Gillen & Grill’s (2023) analysis of dementia trial retention data. Therefore, recruitment will aim to exceed the estimated sample size by 10% to ensure the study is adequately powered.

The authors do not completely adhere to the reporting statement. It remains unclear who will be in charge of the implementation of the allocation sequence and how this will be done.

Random allocation will be completed by one of the principal investigator’s academic supervisors who are otherwise uninvolved in the conduct of the study

Where will the intervention take place? Please add information.

Intervention will take place at the clinical sites where recruitment will take place. CS-ADL groups will be facilitated in available group therapy/ occupational therapy rooms available.

Do the authors plan to implement a control mechanism whether blinding was successful?

The success of blinding will be tested following completion of outcome measures by asking assessors to guess the treatment assignment of participants, expressing either a treatment guess or uncertainty. If blinding is successful, ‘do not know’ guesses should be high, and incorrect guesses should be balanced (Kolahi, Bang & Park, 2009). While it is possible that unblinding might occur, i.e., outcome assessors become aware of group allocation, the process of blinding will be explained to participants, and they will be asked to not reveal their treatment allocation to the assessor.

A figure displaying the participant timelime is missing.

Apologies for this error. The figure in question has been uploaded with this resubmission.

It remains unclear why an audit is not planned. Please comment on this. An audit would guarantee the quality of study procedures and data.

While it is acknowledged that an audit would ensure the quality of study processes, traditional auditing methods are expensive and due to constraints on budget and resources for this study, a formal audit process will not be completed. The researcher will instead attend carefully to the research design throughout the process of the study. Furthermore, careful thought and consideration has gone into the planning of the pragmatics of the study to ensure processes are feasible within the clinical settings in which the study is run, to minimise deviations from the protocol.

Attachments
Attachment
Submitted filename: Rebuttal letter.docx
Decision Letter - Sascha Köpke, Editor

Cognitive stimulation in activities of daily living for individuals with mild-to-moderate dementia (CS-ADL): study protocol for a randomised controlled trial.

PONE-D-23-41253R1

Dear Dr. Ryan,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Sascha Köpke

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #2: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Thank you for the revision.

By adding methodological details about the randomisation and the UK MRC Framework, the transparency of the manuscript has improved very much.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Sascha Köpke, Editor

PONE-D-23-41253R1

PLOS ONE

Dear Dr. Ryan,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Sascha Köpke

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .